ZURICH, July 19, 2010 /PRNewswire/ — Today, Novo
Nordisk announced the landmark recruitment of the 60,000th patient
in the A1chieve(R) study – an observational study designed to
investigate the effects of modern insulins in the management of
type 2 diabetes.[1]
Spanning 28 countries across 4 continents and involving more
than 3300 physicians, A1chieve(R) is set to be the world’s largest
observational study in insulin therapy.
Approximately 70 percent of the world’s 285 million people with
diabetes are living in these 28 emerging countries where there is a
rising need and interest to look at differences in physician
decisions in the management of diabetes.[2]
“Multinational observational studies like A1chieve(R) provide
valuable insights in the way current therapies are applied when it
comes to varying cultural, economic and epidemiological
circumstances,” said Philip Home,
Professor of Diabetes Medicine at Newcastle University England and
Chair of the A1chieve(R) Global Advisory Board.
In order to mimic the natural secretion of insulin in the body,
commercially available insulin preparations are used in different
ways (regimens) based on an individual’s need and prevailing local
practices. However it is important to evaluate these different
regimens in a real life setting.
“Once completed A1chieve(R) will provide locally relevant
information on the effective use of modern insulins across
different regimens. This information could be further useful to
inform and improve the local guidelines on the management of type 2
diabetes” added Professor Home.
Jesper H0iland, Senior Vice President, Novo Nordisk Region
International Operations A
‘/>”/>
